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Decreased cerebral protein and activity levels of glutamine synthetase (GS) have been reported for
Alzheimer’s disease (AD) patients. Using a recently established method, we quantiﬁed total GS levels in
cerebrospinal ﬂuid (CSF) from AD patients and control subjects. Furthermore, we investigated if total GS
levels in CSF could differentiate AD from frontotemperal dementia and dementia with Lewy bodies
patients. As we found no signiﬁcantly altered total GS levels in any of the patient groups compared with
control subjects, we conclude that levels of total GS in CSF have no diagnostic value for AD, dementia
with Lewy bodies, or frontotemperal dementia.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Abnormal levels of glutamine synthetase (GS), an astrocytic
enzyme that regulates levels of glutamate and ammonia in the
brain (Rose et al., 2013), have been reported in Alzheimer’s disease
(AD) brains. Both the native multimeric form and the 44 kDa
monomeric form of GS (Boksha et al., 2002) have been investigated
for their potential as cerebrospinal ﬂuid (CSF) biomarkers for AD.
One study demonstrated the presence of monomeric GS in 38 of 39
AD CSF samples, whereas only one of 29 control samples had a
detectable level of GS (Gunnersen and Haley, 1992). In another
study, using a sandwich enzyme-linked immunosorbent assay
(ELISA) that does not detect monomeric GS (Tumani et al., 1995),
CSF levels of multimeric GS were found increased in AD (Tumani
et al., 1999).
Recently, we developed a protocol that unmasks protein epi-
topes by applying acidiﬁcation and subsequent neutralization to
CSF (AFBN protocol) (Herbert et al., 2012). The AFBN protocol was
shown to dissemblemultimeric GS intomonomeric GS proteins andy, Donders Institute for Brain,
Radboud University Medical
the Netherlands. Tel.: þ1 31
.M. Verbeek).
ll rights reserved.therefore allows for the quantiﬁcation of total levels of GS. Applying
the AFBN protocol into a homemade ELISA (Herbert et al., 2012), we
now aimed to quantify levels of total GS, whichdbased on the
previously reported increased levels of monomeric and multimeric
GSdwe expect to be increased in CSF samples of AD patients
compared with control CSF samples. Additionally, we compared
total GS levels in AD with those in frontotemporal dementia (FTD)
and dementia with Lewy bodies (DLB), to investigate the biomarker
potential of CSF GS in the differential diagnosis of various types of
dementia. CSF levels of the established biomarkers Ab42, total tau
(t-tau), and phosphorylated tau (p-tau) were determined to study
potential correlations.
2. Methods
This study included CSF samples of 26 control subjects, 34 AD
patients, 21 DLB patients, and 19 FTD patients (for demographics
see Table 1) obtained by lumbar puncture between 2000 and 2009.
Total GS levels were measured in AFBN-pretreated CSF using a
homemade ELISA as previously described (Herbert et al., 2012).
Ab42, t-tau, and p-tau levels were determined using commercially
available ELISA kits (Fujirebio Europe, Ghent, Belgium). Statistical
analysis on non-Gaussian distributed data was performed using
Kruskal-Wallis tests with Dunn Multiple Comparison post hoc
Table 1
Demographics and CSF protein levels of control and dementia groups given as median (25the75th percentile)
Controls (n ¼ 26) AD (n ¼ 34) FTD (n ¼ 21) DLB (n ¼ 19) p
Age (y) 65 (59e77) 72 (65e77) 65 (60e73) 73 (64e79) NSa
Males (%) 62 34ǂ 67 100 <0.0001a
MMSE score 28 (24e29) (n ¼ 5) 21 (19e23) (n ¼ 29)* 22 (15e25) (n ¼ 16) 24 (22e28) (n ¼ 9) <0.05a
Ab42 (pg/mL) 789 (519e976) 449 (354e503)*,# 752 (573e943) 545 (400e678)*,# <0.0001b
T-tau (pg/mL) 300 (196e390) 653 (356e736)*,#,ǂ 335 (241e401) 214 (166e290) <0.0001a
P-tau (pg/mL) 57 (47e73) 106 (71e132)*,#,ǂ 58 (51e85) 46 (38e61) <0.0001a
GS (ng/mL) 64 (45e108) 75 (53e95) 90 (61e127) 88 (65e122) NSa
*p < 0.05 versus control, # p < 0.05 versus FTD, ǂp < 0.05 versus DLB.
Key: AD, Alzheimer’s disease; ANOVA, analysis of variance; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; GS, glutamine synthetase; MMSE, mini-mental
state examination; NS, nonsigniﬁcant; p-tau, phosphorylated tau; SD, standard deviation; t-tau, total tau.
a Kruskal-Wallis test (Dunn Multiple Comparison post hoc tests).
b ANOVA (Bonferroni post hoc tests).
N.M. Timmer et al. / Neurobiology of Aging 36 (2015) 1271e12731272analysis. On Gaussian distributed data, 1-way ANOVA with Bon-
ferroni post hoc analysis was performed. To investigate correlations
between different markers, the Spearman method was performed.
Detailed methods are provided in the Supplemental Data.3. Results
There was no difference in age between the various groups
(Table 1, p ¼ 0.09), but gender distribution did differ between the
groups (Table 1, p < 0.0001). The post hoc test revealed a difference
for gender distribution between AD and DLB (p < 0.001). MMSE
scores also differed between groups (Table 1, p ¼ 0.01) with post
hoc analysis revealing a lower score in AD patients versus controls,
as expected (p < 0.05). Correlation analysis revealed no association
between total GS levels in CSF and MMSE score and age or gender
(data not shown).
Therewere no differences in total GS levels between the different
patient groups and control subjects (Fig. 1 and Table 1, p ¼ 0.20).
Levels of the established AD biomarker Ab42 (Table 1) were lower in
AD and DLB patients compared with control subjects (both p <
0.001) and FTD patients (p< 0.001 and p< 0.01, respectively). There
was no difference in Ab42 levels between control subjects and FTD
patients or between AD and DLB patients (Table 1). T-tau and p-tau
levels were higher in AD patients compared with control subjects
(bothp<0.001), DLBpatients (both p<0.001), and FTDpatients (p<
0.05 and p< 0.01, respectively), while neither t-tau nor p-tau levels
differed between the latter groups (Table 1).
Correlation analysis demonstrated a negative correlation
between t-tau and total GS (r ¼ 0.45, p ¼ 0.008) and between
p-tau and total GS (r ¼ 0.48, p ¼ 0.004) in the AD group
(Supplementary Fig. 1). There was no correlation between t-tau orFig. 1. Total CSF GS levels (ng/mL) in controls (n ¼ 26) and dementia patients (AD:
n ¼ 34; FTD: n ¼ 21; DLB: n ¼ 19). Abbreviations: AD, Alzheimer’s disease; CSF,
cerebrospinal ﬂuid; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia;
GS, glutamine synthetase.p-tau levels and total GS in control subjects, DLB, or FTD patients
(data not shown). Total GS levels in CSF did not correlate with CSF
Ab42 levels in any group (data not shown).4. Discussion
Previously, in 2 separate studies increased concentrations of both
monomeric and multimeric GS were found in CSF samples of AD
patients compared with nondemented control subjects (Gunnersen
and Haley, 1992; Tumani et al., 1999). We now performed a quanti-
tative measurement of total GS and found that the level of total GS in
CSF did not differ between control subjects and AD patients.
Furthermore, although the relative speciﬁcity of elevated (mono-
meric) GS levels for AD compared with other neurologic diseases
(e.g., Parkinson’s disease, amyotrophic lateral sclerosis, and Pick
disease) was previously demonstrated (Gunnersen and Haley, 1992),
we could not ﬁnd a similar speciﬁcity for total GS in CSF when
comparing AD with DLB or FTD. Correlation analysis revealed a
negative correlation between total GS and (phosphorylated) tau
levels speciﬁcally in the CSF of AD patients that may warrant further
investigation.
There are a few possible explanations for the discrepancies be-
tween our study and the previous studies on GS in CSF (Gunnersen
and Haley, 1992; Tumani et al., 1999). First, differences in the source
of CSF may have affected the results. Although we used lumbar
CSF, a previous study measured GS mostly in ventricular CSF
(Gunnersen and Haley, 1992). Indeed, the number of lumbar
CSF samples used in both previous studies was lower than in our
study. Second, the previously reported photolabeling technique to
measure monomeric GS levels (Gunnersen and Haley,1992) is a less
quantitative method than the ELISA measurements we used.
In conclusion, our study suggests that total GS levels in CSF is not
a suitable biomarker for AD and does not conﬁrm the previously
suggested biomarker potential for both monomeric and multimeric
GS. This ﬁnding is in line with a recent study that disproved the
potential of serum GS levels as a diagnostic tool in AD (Vermeiren
et al., 2011). More extensive studies may be needed to conﬁrm
the diagnostic value of either multimeric or monomeric GS for AD.Disclosure statement
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
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